Janine M. Lupo1, Caroline A. Racine2, Angela Jakary1, Sarah J. Nelson1, 3, Susan M. Chang4, Nicholas Butowski2
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States; 2Department of Neurological Surgery, University of California, San Francisco, CA, United States; 3Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, United States; 4Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States
The current frameworks for understanding neurocognitive changes over time in patients with glioma are still limited, and would benefit from correlation with imaging in order to gain insight into the pathogenesis of treatment-related brain injury. We performed a pilot study that aimed to identify quantitative physiological parameters obtained from diffusion-weighted, perfusion-weighted, and spectroscopic MR imaging prior to surgery and subsequent therapy that can relate to measured neurocognitive impairment before, during, and after the course of standard treatment regimes. Perfusion parameters were most often associated with cognitive measures in general, with normal-appearing brain regions driving associations at later time points.